UNSPSC 51132205: Acetaminophen/aspirin/caffeine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN103. This VA Drug Class (CN103) classifies this compound as belonging to the group NON-OPIOID ANALGESICS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51132205 Acetaminophen/aspirin/caffeine is a Commodity code that in recent state and local procurement activity covers a broader range of pharmaceutical and over-the-counter products than the code name suggests—including naloxone, drug deactivation systems, generic multi-source pharmaceuticals, and OTC items supplied through authorized wholesale channels. State and local health departments, cooperative purchasing alliances, and county health agencies are the primary issuing bodies, with the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and county health systems in Florida and Texas representing recent activity. Solicitations emphasize compliance with current Good Manufacturing Practices, Drug Supply Chain Security Act certification, E-Verify and drug-free workplace requirements, and specific insurance coverages including commercial general liability and professional liability. Vendors typically must maintain relationships with authorized wholesalers and provide detailed product information including National Drug Codes, pricing in multiple formats (flat price, net price, WAC-minus), and quarterly or ongoing delivery schedules to designated facilities.

Recent activity spans Florida, Minnesota, and Texas. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries (response deadline July 26, 2023). The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription fulfillment capabilities, signaling future formal procurement. MMCAP, administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 to establish multi-award contracts for generic pharmaceuticals and OTC products across participating states and local facilities, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; evaluation favors price competitiveness (75 percent weight) with mandatory 3 percent administrative fees and performance penalties for reporting and onboarding delays.